Susanna S. Ng

University Hospital Bonn — Germany

Immunology and Microbiology · Life Sciences

20h-index2.0kcitations75works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(37), Research on Leishmaniasis Studies(16), Cancer Immunotherapy and Biomarkers(15), CAR-T cell therapy research(11), Malaria Research and Control(6)

Publications75 total

Longitudinal spatial profiling of neutrophils during adoptive T cell therapy in murine melanoma reveals distinct lymph node infiltration patterns across anatomical sites
2026
Supplementary Figures from NKG7 Is Required for Optimal Antitumor T-cell Immunity
2025Open Access
Figure S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025· 1 citedOpen Access
Table S3 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S5 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Data from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Figure S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Figure S3 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S7 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S6 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Table S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Figure S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
2025Open Access
Flow cytometry protocol for cell death analysis in glioblastoma organoids: A technical note
PLoS ONE·2025Open Access
Defining the roles of NKG7 expressed by CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells during malaria
2025Open Access
The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Molecular Cancer Therapeutics·2025· 4 cited
NKG7 is a Stable Marker of Cytotoxicity Across Immune Contexts and Within the Tumor Microenvironment
European Journal of Immunology·2025· 4 citedOpen Access
Author response for "NKG7 is a Stable Marker of Cytotoxicity Across Immune Contexts and Within the Tumor Microenvironment"
2025
Author response for "NKG7 is a Stable Marker of Cytotoxicity Across Immune Contexts and Within the Tumor Microenvironment"
2025
page 1 of 4Next →

Frequent Co-authors

Christian Engwerda(36), Fabian de Labastida Rivera(24), Rajiv Kumar(23), Marcela Montes de(21), Fiona H. Amante(21), Chelsea L. Edwards(21), Patrick T. Bunn(17), Dillon Corvino(15), Teija Frame(13), Michael Hölzel(12), Mark J. Smyth(12), Shashi Bhushan Chauhan(11), Yulin Wang(11), Jessica A. Engel(10), Ashraful Haque(10), Geoffrey R. Hill(10), Rebecca J. Faleiro(10), Shyam Sundar(10), Marieta Toma(10), Tobias Bald(9)